Evercore ISI Group analyst Gavin Clark-Gartner initiates coverage on Foghorn Therapeutics (NASDAQ:FHTX) with a Outperform rating and announces Price Target of $20.
Evercore ISI Group Initiates Coverage On Foghorn Therapeutics With Outperform Rating, Announces Price Target of $20
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.